自杀风险的躯体治疗更新
本综述汇总随机对照试验、荟萃分析、国家注册研究及大型药物流行病学与队列研究,评估药物与神经调控干预对自杀死亡、自杀未遂或自杀意念的影响。锂盐和氯氮平可能减少双相障碍和精神分裂症谱系障碍的自杀行为,静脉氯胺酮快速降低自杀意念,但获益多为一过性,且研究对自杀行为检验效能不足。
要点
- 锂盐与氯氮平分别与双相障碍和精神分裂症谱系障碍自杀行为减少相关,机制超越疾病稳定。
- 静脉氯胺酮在RCT中快速降低自杀意念,部分独立于抗抑郁效应,但获益多为一过性。
- 抗抑郁药主要通过改善抑郁症状降低自杀意念,观察性研究多发现自杀行为风险降低。
核心结论
- 躯体治疗可降低自杀意念,部分情况下降低自杀行为风险,效应多由抗抑郁或心境稳定机制介导。
- 氯氮平和锂盐可能预防自杀行为,静脉氯胺酮可能通过额外作用于自杀素质降低自杀意念。
- 针对自杀行为素质的治疗策略尚待探索,需足够效能的RCT检验躯体治疗对自杀行为的影响。
研究设计与样本
- 范围综述,综合随机对照试验、荟萃分析、国家注册研究及大型药物流行病学与队列研究。
- 评估药物与神经调控治疗与自杀死亡、自杀未遂或自杀意念结局的关联。
- 研究依据设计、样本量、人群和结局定义进行评价。
主要发现
- 锂盐和氯氮平分别与双相障碍和精神分裂症谱系障碍的自杀行为减少相关,机制超越疾病稳定。
- 静脉氯胺酮在RCT中快速降低自杀意念,部分独立于抗抑郁效应,但获益多为一过性,研究对自杀行为检验效能不足。
- 抗抑郁药在RCT中主要通过改善抑郁症状降低自杀意念,研究对自杀行为检验效能通常不足。
- 观察性研究和患者水平RCT荟萃分析一般发现自杀行为风险降低。
- 阿片使用障碍药物在观察性研究中与自杀和过量死亡降低相关。
关键数值与推荐
- 电休克治疗快速降低自杀意念和自杀死亡率。
- 经颅磁刺激似乎主要通过抗抑郁效应降低自杀意念。
- 阿片使用障碍药物在观察性研究中与自杀和过量死亡死亡率降低相关。
临床怎么用
- 对双相障碍和精神分裂症谱系障碍高自杀风险患者,可考虑锂盐或氯氮平以降低自杀行为风险。
- 静脉氯胺酮可用于快速降低自杀意念,但需注意获益多为一过性。
- 抗抑郁药通过改善抑郁症状降低自杀意念,对自杀行为的影响需结合观察性证据综合评估。
局限性
- 多数研究对自杀行为结局检验效能不足。
- 部分获益为短暂性,长期效应不确定。
- 针对自杀素质的治疗策略研究有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Suicide is a major cause of death worldwide and a key public health challenge. Pharmacologic and neuromodulatory interventions are central to suicide prevention. This review summarizes evidence for these interventions with potential antisuicidal effects across major psychiatric disorders and, where possible, distinguishes their direct effects on suicide diathesis from those mediated by psychiatric symptom improvement. METHODS: This scoping review synthesized evidence from randomized controlled trials (RCTs), meta-analyses, national registry studies, and large pharmacoepidemiologic and cohort studies to examine associations between pharmacologic and neuromodulatory treatments and suicide deaths, suicide attempts, or suicidal ideation as outcomes. Studies were appraised based on design, sample size, population, and outcome definitions. RESULTS: Lithium and clozapine were associated with reductions in suicidal behavior in bipolar disorder and schizophrenia spectrum disorders, respectively, mediated by mechanisms beyond disease stabilization. Intravenous ketamine rapidly reduced suicidal ideation in RCTs, partially independent of antidepressant effects. Benefit was generally transient, and studies were not powered for suicidal behavior. Antidepressants reduced suicidal ideation primarily through improvement in depressive symptoms in RCTs that were generally underpowered to determine effects on suicidal behavior. Observational and patient-level RCT meta-analyses generally found reduced suicidal behavior risk. Opioid use disorder medications were associated with lowered suicide and overdose mortality in observational studies. Electroconvulsive therapy rapidly reduced suicidal ideation and suicide mortality, and transcranial magnetic stimulation appeared to reduce suicidal ideation primarily via antidepressant effects. CONCLUSIONS: Somatic treatments reduce suicidal ideation and, in some cases, suicidal behavior risk, with effects mostly mediated by antidepressant or mood-stabilizing mechanisms. Clozapine and lithium may prevent suicidal behavior, and intravenous ketamine may reduce suicidal ideation through additional effects on suicide diathesis. Targeting the diathesis for suicidal behavior is a largely unexplored therapeutic strategy. Adequately powered RCTs to test somatic treatment effects on suicidal behavior are essential for evidence-based suicide prevention.
引用
- Rizk MM, Mann JJ. An Update on Somatic Treatments for Suicide Risk. Am J Psychiatry. 2026. PMID: 42219565. doi:10.1176/appi.ajp.20260287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。